Who is sponsoring NCT03666221?

NCT03666221 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT03666221?

Interventions in NCT03666221: Nimotuzumab.

What condition does NCT03666221 study?

NCT03666221 studies Recurrent Nasopharyngeal Carcinoma.

Is NCT03666221 still recruiting?

NCT03666221 is currently status unknown. Last updated 11 September 2018.

Last reviewed 2018-09-11 · How we verify

NCT03666221

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Status unknown Phase 2 Last updated 11 September 2018

What this trial tests

Phase 2 trial testing Nimotuzumab in Recurrent Nasopharyngeal Carcinoma in 67 participants. Status unknown.

Timeline

1 November 2014

Primary endpoint
1 April 2020

1 November 2022

Quick facts

Lead sponsor	Fujian Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	67
Start date	1 November 2014
Primary completion	1 April 2020
Estimated completion	1 November 2022
Sites	1 location across China

Drugs / interventions tested

Nimotuzumab — full drug profile →

Conditions studied

Recurrent Nasopharyngeal Carcinoma — all drugs for Recurrent Nasopharyngeal Carcinoma →

Sponsor

Fujian Cancer Hospital

Who can join

Adults 18 to 70, any sex, with Recurrent Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study assessed the clinical efficacy, and safety of the combination of Nimotuzumab administered concomitantly with intensity modulated radiation therapy(IMRT) in patients with recurrent nasopharyngeal cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.
Siak PY, Heng WS, Teoh SSH, Lwin YY, et al · · 2023 · cited 33× · PMID 37932756 · DOI 10.1186/s12967-023-04673-8
Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma.
Zong JF, Liang QD, Lu QJ, Liu YH, et al · · 2021 · cited 8× · PMID 34823489 · DOI 10.1186/s12885-021-08995-y

Verify or expand the search:

Other trials of Nimotuzumab

Trials testing the same drug.

NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
NCT07457528 — Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC · Phase 2 · recruiting
NCT07445048 — Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck · Phase 3 · recruiting
NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
NCT07277452 — Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline R · Phase 2 · not yet recruiting

Other recruiting trials for Recurrent Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT07412314 — Proton Therapy for Recurrent Nasopharyngeal Carcinoma · NA · recruiting
NCT06029270 — Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta · Phase 2 · recruiting
NCT06235203 — Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC · Phase 3 · recruiting
NCT06228079 — Adjuvant vs Surgery Only in Early-stage Recurrent NPC · Phase 3 · recruiting
NCT05904080 — Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, · Phase 2 · recruiting

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03666221 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 11 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03666221.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing